Jeffrey H Kordower

List of Publications by Year
in descending order

237	31,118	5268	4645
papers	citations	83 h-index	170 g-index

244	244	244	22246
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinsonâ€™s disease. Nature, 2011, 480, 547-551.	27.8	1,603
2	Lewy bodyâ€“like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Medicine, 2008, 14, 504-506.	30.7	1,472
3	A doubleâ€blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Annals of Neurology, 2003, 54, 403-414.	5.3	1,450
4	Neurodegeneration Prevented by Lentiviral Vector Delivery of GDNF in Primate Models of Parkinson's Disease. Science, 2000, 290, 767-773.	12.6	1,201
5	A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nature Medicine, 2005, 11, 551-555.	30.7	979
6	Disease duration and the integrity of the nigrostriatal system in Parkinsonâ€™s disease. Brain, 2013, 136, 2419-2431.	7.6	965
7	Neuropathological Evidence of Graft Survival and Striatal Reinnervation after the Transplantation of Fetal Mesencephalic Tissue in a Patient with Parkinson's Disease. New England Journal of Medicine, 1995, 332, 1118-1124.	27.0	868
8	Increased Intestinal Permeability Correlates with Sigmoid Mucosa alpha-Synuclein Staining and Endotoxin Exposure Markers in Early Parkinson's Disease. PLoS ONE, 2011, 6, e28032.	2.5	689
9	Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Annals of Neurology, 2002, 51, 145-155.	5.3	639
10	Missing pieces in the Parkinson's disease puzzle. Nature Medicine, 2010, 16, 653-661.	30.7	621
11	Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurology, The, 2010, 9, 1164-1172.	10.2	589
12	Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Annals of Neurology, 1995, 38, 379-388.	5.3	421
13	Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Annals of Neurology, 2001, 49, 202-213.	5.3	397
14	Selective inhibition of NF-Î²B activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18754-18759.	7.1	391
15	Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Annals of Neurology, 1999, 46, 419-424.	5.3	386
16	Is alphaâ€synuclein in the colon a biomarker for premotor Parkinson's Disease? Evidence from 3 cases. Movement Disorders, 2012, 27, 716-719.	3.9	383
17	Alphaâ€synuclein in colonic submucosa in early untreated Parkinson's disease. Movement Disorders, 2012, 27, 709-715.	3.9	381
18	Age-associated increases of Î±-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?. Neurobiology of Disease, 2007, 25, 134-149.	4.4	362

#	Article	IF	Citations
19	Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions. Neurobiology of Disease, 2009, 35, 385-398.	4.4	360
20	Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nature Reviews Neuroscience, 2011, 12, 359-366.	10.2	358
21	Long-term Evaluation of Bilateral Fetal Nigral Transplantation in Parkinson Disease. Archives of Neurology, 1999, 56, 179.	4.5	347
22	TrkAâ€immunoreactive profiles in the central nervous system: Colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin. Journal of Comparative Neurology, 1994, 350, 587-611.	1.6	321
23	The role of Î±-synuclein in Parkinson's disease: insights from animal models. Nature Reviews Neuroscience, 2003, 4, 727-738.	10.2	317
24	Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature, 1997, 386, 395-399.	27.8	310
25	Role of TLR4 in the gut-brain axis in Parkinsonâ€™s disease: a translational study from men to mice. Gut, 2019, 68, 829-843.	12.1	290
26	Functional fetal nigral grafts in a patient with Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies. , 1996, 370, 203-230.		286
27	Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: A quantitative analysis across subregions of the basal forebrain. Experimental Neurology, 1989, 105, 221-232.	4.1	271
28	Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Movement Disorders, 1998, 13, 383-393.	3.9	271
29	Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. Journal of Comparative Neurology, 1998, 401, 253-265.	1.6	267
30	Alterations in axonal transport motor proteins in sporadic and experimental Parkinsonâ€™s disease. Brain, 2012, 135, 2058-2073.	7.6	249
31	Transplanted dopaminergic neurons develop PD pathologic changes: A second case report. Movement Disorders, 2008, 23, 2303-2306.	3.9	247
32	Nerve growth factor receptor immunoreactive profiles in the normal, aged human basal forebrain: Colocalization with cholinergic neurons. Journal of Comparative Neurology, 1989, 285, 196-217.	1.6	242
33	Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Annals of Neurology, 2006, 60, 706-715.	5.3	235
34	Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. Journal of Comparative Neurology, 2004, 475, 211-219.	1.6	232
35	Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. Journal of Comparative Neurology, 2000, 427, 19-30.	1.6	225
36	Gene delivery of neurturin to putamen and substantia nigra in <scp>P</scp>arkinson disease: A doubleâ€blind, randomized, controlled trial. Annals of Neurology, 2015, 78, 248-257.	5.3	224

#	Article	IF	Citations
37	Putative chromaffin cell survival and enhanced host-derived TH-Fiber innervation following a functional adrenal medulla autograft for Parkinson's disease. Annals of Neurology, 1991, 29, 405-412.	5.3	209
38	Nerve growth factor in AlzheimerÊ¼s disease: defective retrograde transport to nucleus basalis. NeuroReport, 1995, 6, 1063-1066.	1.2	206
39	Implants of Encapsulated Human CNTF-Producing Fibroblasts Prevent Behavioral Deficits and Striatal Degeneration in a Rodent Model of Huntingtonâ€™s Disease. Journal of Neuroscience, 1996, 16, 5168-5181.	3.6	204
40	Progression of intestinal permeability changes and alphaâ€synuclein expression in a mouse model of Parkinson's disease. Movement Disorders, 2014, 29, 999-1009.	3.9	202
41	Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins. Acta Neuropathologica, 2017, 134, 629-653.	7.7	201
42	Therapeutic approaches to target alpha-synuclein pathology. Experimental Neurology, 2017, 298, 225-235.	4.1	197
43	Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: Rescue and sprouting of degenerating cholinergic basal forebrain neurons. Journal of Comparative Neurology, 1994, 349, 148-164.	1.6	196
44	Loss of basal forebrain P75^{NTR} immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. Journal of Comparative Neurology, 2002, 443, 136-153.	1.6	195
45	Aging and Parkinson's disease: Different sides of the same coin?. Movement Disorders, 2017, 32, 983-990.	3.9	192
46	Nurr1 in Parkinson's disease and related disorders. Journal of Comparative Neurology, 2006, 494, 495-514.	1.6	190
47	Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. Journal of Comparative Neurology, 2002, 450, 203-214.	1.6	187
48	Estrogen increases the number of spinophilinâ€immunoreactive spines in the hippocampus of young and aged female rhesus monkeys. Journal of Comparative Neurology, 2003, 465, 540-550.	1.6	187
49	Lentivirally Delivered Glial Cell Line-Derived Neurotrophic Factor Increases the Number of Striatal Dopaminergic Neurons in Primate Models of Nigrostriatal Degeneration. Journal of Neuroscience, 2002, 22, 4942-4954.	3.6	187
50	Lentiviral Gene Transfer to the Nonhuman Primate Brain. Experimental Neurology, 1999, 160, 1-16.	4.1	186
51	Animal Models of Huntington's Disease. ILAR Journal, 2007, 48, 356-373.	1.8	185
52	Nerve growth factor receptor immunoreactivity in the nonhuman primate (Cebus apella): Distribution, morphology, and colocalization with cholinergic enzymes. Journal of Comparative Neurology, 1988, 277, 465-486.	1.6	183
53	Reduction in p140-TrkA Receptor Protein within the Nucleus Basalis and Cortex in Alzheimer's Disease. Experimental Neurology, 1997, 146, 91-103.	4.1	175
54	A phase1 study of stereotactic gene delivery of AAV2â€NGF for Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 571-581.	0.8	173

#	Article	IF	Citations
55	Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease. Neurobiology of Disease, 2020, 135, 104352.	4.4	172
56	Substantia nigra tangles are related to gait impairment in older persons. Annals of Neurology, 2006, 59, 166-173.	5.3	164
57	Galanin immunoreactivity in the primate central nervous system. Journal of Comparative Neurology, 1992, 319, 479-500.	1.6	161
58	Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: Diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiology of Disease, 2007, 26, 56-65.	4.4	150
59	Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat. Neurobiology of Disease, 2011, 43, 552-557.	4.4	149
60	Bioactivity of AAV2â€neurturin gene therapy (CEREâ€120): Differences between Parkinson's disease and nonhuman primate brains. Movement Disorders, 2011, 26, 27-36.	3.9	144
61	Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinsonâ€™s disease. Science Translational Medicine, 2016, 8, 368ra174.	12.4	143
62	Proteasome inhibition and Parkinson's disease modeling. Annals of Neurology, 2006, 60, 260-264.	5.3	138
63	Neurotrophic factor therapy for Parkinsonâ€™s disease. Progress in Brain Research, 2010, 184, 237-264.	1.4	138
64	AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinsonâ€™s disease. Neurobiology of Disease, 2007, 27, 67-76.	4.4	134
65	Differential vulnerability of neurons in Huntingtonâ€™s disease: the role of cell typeâ€specific features. Journal of Neurochemistry, 2010, 113, 1073-1091.	3.9	130
66	Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Annals of Neurology, 2006, 60, 264-268.	5.3	128
67	Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. Neurobiology of Disease, 2018, 112, 106-118.	4.4	127
68	Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Movement Disorders, 2007, 22, 1124-1132.	3.9	126
69	Early changes in Huntingtonâ€™s disease patient brains involve alterations in cytoskeletal and synaptic elements. Journal of Neurocytology, 2004, 33, 517-533.	1.5	122
70	Galaninâ€like immunoreactivity within the primate basal forebrain: Differential staining patterns between humans and monkeys. Journal of Comparative Neurology, 1990, 294, 281-292.	1.6	119
71	Trophic Factor Gene Therapy for Parkinson's Disease. Movement Disorders, 2013, 28, 96-109.	3.9	113
72	Fetal Grafting for Parkinson's Disease: Expression of Immune Markers in Two Patients with Functional Fetal Nigral Implants. Cell Transplantation, 1997, 6, 213-219.	2.5	107

#	Article	IF	Citations
73	In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease. Annals of Neurology, 2003, 53, S120-S134.	5.3	105
74	Human autologous iPSCâ€“derived dopaminergic progenitors restore motor function in Parkinsonâ€™s disease models. Journal of Clinical Investigation, 2020, 130, 904-920.	8.2	102
75	Alphaâ€synuclein propagation: New insights from animal models. Movement Disorders, 2016, 31, 161-168.	3.9	100
76	Doublecortin expression in adult cat and primate cerebral cortex relates to immature neurons that develop into GABAergic subgroups. Experimental Neurology, 2009, 216, 342-356.	4.1	98
77	Nerve growth factor receptor and choline acetyltransferase remain colocalized in the nucleus basalis (Ch4) of Alzheimer's patients. Neurobiology of Aging, 1989, 10, 67-74.	3.1	96
78	Dopaminergic Transplants in Patients with Parkinson's Disease: Neuroanatomical Correlates of Clinical Recovery. Experimental Neurology, 1997, 144, 41-46.	4.1	96
79	Grafts of EGF-responsive neural stem cells derived from GFAP-hNGF transgenic mice: Trophic and tropic effects in a rodent model of Huntington's disease. , 1997, 387, 96-113.		96
80	Estrogen receptor immunoreactivity within subregions of the rat forebrain: neuronal distribution and association with perikarya containing choline acetyltransferase. Brain Research, 1999, 849, 253-274.	2.2	96
81	PGCâ^'1Î± Promoter Methylation in Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0134087.	2.5	95
82	Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9345-9350.	7.1	94
83	Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiology of Disease, 2006, 21, 165-180.	4.4	93
84	Extensive neuroprotection by choroid plexus transplants in excitotoxin lesioned monkeys. Neurobiology of Disease, 2006, 23, 471-480.	4.4	89
85	Lewy body pathology in fetal grafts. Annals of the New York Academy of Sciences, 2010, 1184, 55-67.	3.8	87
86	Etiology of Parkinson's disease: Genetics and environment revisited. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13972-13974.	7.1	84
87	Structural and functional neuroprotection in a rat model of Huntingtonâ€™s disease by viral gene transfer of GDNF. Experimental Neurology, 2003, 181, 213-223.	4.1	84
88	Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind videoâ€based analysis. Movement Disorders, 2009, 24, 336-343.	3.9	84
89	Doublecortin-expressing cells persist in the associate cerebral cortex and amygdala in aged nonhuman primates. Frontiers in Neuroanatomy, 2009, 3, 17.	1.7	82
90	Differential Transduction Following Basal Ganglia Administration of Distinct Pseudotyped AAV Capsid Serotypes in Nonhuman Primates. Molecular Therapy, 2010, 18, 579-587.	8.2	82

#	Article	IF	Citations
91	Dopaminergic transplantation for parkinson's disease: Current status and future prospects. Annals of Neurology, 2009, 66, 591-596.	5.3	80
92	Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. Brain, 2019, 142, 3565-3579.	7.6	80
93	EXPRESSION, BIOACTIVITY, AND SAFETY 1 YEAR AFTER ADENO-ASSOCIATED VIRAL VECTOR TYPE 2â€“MEDIATED DELIVERY OF NEURTURIN TO THE MONKEY NIGROSTRIATAL SYSTEM SUPPORT CERE-120 FOR PARKINSON'S DISEASE. Neurosurgery, 2009, 64, 602-613.	1.1	75
94	Temporal evolution of microglia and Î±-synuclein accumulation following foetal grafting in Parkinsonâ€™s disease. Brain, 2019, 142, 1690-1700.	7.6	75
95	B2 bradykinin receptor immunoreactivity in rat brain. Journal of Comparative Neurology, 2000, 427, 1-18.	1.6	72
96	Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism. Experimental Neurology, 2005, 191, S60-S67.	4.1	72
97	Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a <scp>P</scp>arkinson disease patient. Annals of Neurology, 2017, 81, 46-57.	5.3	72
98	Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Research, 2007, 1147, 77-88.	2.2	71
99	Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: Relevance to selective neuronal vulnerability. Journal of Comparative Neurology, 2007, 502, 683-700.	1.6	70
100	The Critical Role of Nonhuman Primates in Medical Research - White Paper. Pathogens and Immunity, 2017, 2, 352.	3.1	70
101	Neutralization of RANTES and Eotaxin Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson Disease. Journal of Biological Chemistry, 2016, 291, 15267-15281.	3.4	69
102	Chronic ischemic stroke model in cynomolgus monkeys: Behavioral, neuroimaging and anatomical study. Neurological Research, 2003, 25, 68-78.	1.3	68
103	Transgene Expression, Bioactivity, and Safety of CERE-120 (AAV2-Neurturin) Following Delivery to the Monkey Striatum. Molecular Therapy, 2008, 16, 1737-1744.	8.2	68
104	The Potential Role of Gut-Derived Inflammation in Multiple System Atrophy. Journal of Parkinson's Disease, 2017, 7, 331-346.	2.8	68
105	Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes InÂVivo. Stem Cell Reports, 2017, 9, 149-161.	4.8	66
106	T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease. Acta Neuropathologica, 2020, 139, 855-874.	7.7	66
107	Galaninergic Innervation of the Cholinergic Vertical Limb of the Diagonal Band (Ch2) and Bed Nucleus of the Stria terminalis in Aging, Alzheimer's Disease and Down's Syndrome (Part 1 of 2). Dementia and Geriatric Cognitive Disorders, 1993, 4, 237-243.	1.5	65
108	Down-regulation of trkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and Alzheimer's disease. Journal of Comparative Neurology, 2001, 437, 296-307.	1.6	65

#	Article	IF	Citations
109	Trophic factors therapy in Parkinson's disease. Progress in Brain Research, 2009, 175, 201-216.	1.4	64
110	The Prion Hypothesis of Parkinsonâ€™s Disease. Current Neurology and Neuroscience Reports, 2015, 15, 28.	4.2	64
111	GDNF and Parkinsonâ€™s Disease: Where Next? A Summary from a Recent Workshop. Journal of Parkinson's Disease, 2020, 10, 875-891.	2.8	63
112	Proteasome-targeted nanobodies alleviate pathology and functional decline in an Î±-synuclein-based Parkinsonâ€™s disease model. Npj Parkinson's Disease, 2018, 4, 25.	5.3	61
113	Age-related changes in glial cells of dopamine midbrain subregions in rhesus monkeys. Neurobiology of Aging, 2010, 31, 937-952.	3.1	60
114	Nerve growth factor-like immunoreactive profiles in the primate basal forebrain and hippocampal formation. Journal of Comparative Neurology, 1994, 341, 507-519.	1.6	59
115	How strong is the evidence that Parkinson's disease is a prion disorder?. Current Opinion in Neurology, 2016, 29, 459-466.	3.6	59
116	Age and regionâ€specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1â€methylâ€4â€phenylâ€1,2,3,6â€tetrahydropyridine exposure in monkeys. Glia, 2008, 56, 1199-1214.	4.9	57
117	Cell Therapy for Parkinson's Disease: What Next?. Movement Disorders, 2013, 28, 110-115.	3.9	57
118	Endogenous alpha-synuclein monomers, oligomers and resulting pathology: letâ€™s talk about the lipids in the room. Npj Parkinson's Disease, 2019, 5, 23.	5.3	57
119	Î²â€secretaseâ€1 elevation in aged monkey and Alzheimerâ€™s disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and Î²â€amyloid accumulation. European Journal of Neuroscience, 2010, 32, 1223-1238.	2.6	56
120	Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease. Neurobiology of Disease, 2011, 44, 38-52.	4.4	56
121	Gene therapy for Huntington's disease. Neurobiology of Disease, 2012, 48, 243-254.	4.4	56
122	Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease. Neurobiology of Disease, 2014, 69, 1-14.	4.4	56
123	Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinsonâ€™s disease. Brain, 2020, 143, 960-975.	7.6	56
124	Trophic factors for Parkinson's disease: To live or let die. Movement Disorders, 2015, 30, 1715-1724.	3.9	55
125	Huntington's Disease: Pathological Mechanisms and Therapeutic Strategies. Cell Transplantation, 2007, 16, 301-312.	2.5	54
126	Gene transfer of trophic factors and stem cell grafting as treatments for Parkinsonâ€™s disease. Neurology, 2006, 66, S89-103.	1.1	54

#	Article	IF	Citations
127	TRK-immunoreactivity in the monkey central nervous system: Forebrain. Journal of Comparative Neurology, 1994, 349, 20-35.	1.6	53
128	Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiology of Disease, 2009, 34, 40-50.	4.4	53
129	Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. Neurotoxicology and Teratology, 2003, 25, 509-517.	2.4	51
130	Presence of tau pathology within foetal neural allografts in patients with Huntingtonâ€™s and Parkinsonâ€™s disease. Brain, 2017, 140, 2982-2992.	7.6	51
131	Nerve growth factor receptor immunoreactivity within the nucleus basalis (Ch4) in Parkinson's disease: reduced cell numbers and co-localization with cholinergic neurons. Brain Research, 1991, 539, 19-30.	2.2	49
132	Neural Repair Strategies for Parkinson's Disease: Insights from Primate Models. Cell Transplantation, 2006, 15, 251-265.	2.5	49
133	GFAP knockout mice have increased levels of GDNF that protect striatal neurons from metabolic and excitotoxic insults. Journal of Comparative Neurology, 2003, 461, 307-316.	1.6	48
134	Analysis of YFP(J16)-R6/2 reporter mice and postmortem brains reveals early pathology and increased vulnerability of callosal axons in Huntington's disease. Human Molecular Genetics, 2015, 24, 5285-5298.	2.9	48
135	Connections of the hippocampal formation in humans: II. The endfolial fiber pathway. Journal of Comparative Neurology, 1997, 385, 352-371.	1.6	45
136	Anti-Î±-synuclein ASO delivered to monoamine neurons prevents Î±-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys. EBioMedicine, 2020, 59, 102944.	6.1	45
137	Cell Transplantation and Gene Therapy in Parkinson's Disease. Mount Sinai Journal of Medicine, 2011, 78, 126-158.	1.9	43
138	Neuropathology in transplants in Parkinson's disease. Progress in Brain Research, 2012, 200, 221-241.	1.4	43
139	Gene therapy for Parkinson's disease. Movement Disorders, 2010, 25, S161-73.	3.9	42
140	A novel tauâ€based rhesus monkey model of Alzheimer's pathogenesis. Alzheimer's and Dementia, 2021, 17, 933-945.	0.8	42
141	Immunotherapy in Parkinsonâ€™s disease: Current status and future directions. Neurobiology of Disease, 2019, 132, 104587.	4.4	41
142	Lewy body pathology in long-term fetal nigral transplants: is parkinson's disease transmitted from one neural system to another?. Neuropsychopharmacology, 2009, 34, 254-254.	5.4	40
143	Decreased Î±-synuclein expression in the aging mouse substantia nigra. Experimental Neurology, 2009, 220, 359-365.	4.1	39
144	Detecting Alpha Synuclein Seeding Activity in Formaldehyde-Fixed MSA Patient Tissue by PMCA. Molecular Neurobiology, 2018, 55, 8728-8737.	4.0	38

#	Article	IF	Citations
145	Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiology of Disease, 2007, 26, 375-384.	4.4	36
146	Î±-synuclein aggregation reduces nigral myocyte enhancer Factor-2D in idiopathic and experimental Parkinson's disease. Neurobiology of Disease, 2011, 41, 71-82.	4.4	36
147	Is Axonal Degeneration a Key Early Event in Parkinsonâ€™s Disease?. Journal of Parkinson's Disease, 2016, 6, 703-707.	2.8	36
148	Cellular Delivery of CNTF but not NT-4/5 Prevents Degeneration of Striatal Neurons in a Rodent Model of Huntington's Disease. Cell Transplantation, 1998, 7, 213-225.	2.5	35
149	Effects of estrogen replacement therapy on cholinergic basal forebrain neurons and cortical cholinergic innervation in young and aged ovariectomized rhesus monkeys. Journal of Comparative Neurology, 2004, 472, 193-207.	1.6	34
150	Modeling Parkinson's disease. Annals of Neurology, 2009, 66, 432-436.	5.3	34
151	Spreading of alphaâ€synuclein â€“ relevant or epiphenomenon?. Journal of Neurochemistry, 2019, 150, 605-611.	3.9	34
152	Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathologica Communications, 2017, 5, 47.	5.2	33
153	Peripheral alphaâ€synuclein and Parkinson's disease. Movement Disorders, 2014, 29, 963-966.	3.9	32
154	Future of cell and gene therapies for Parkinson's disease. Annals of Neurology, 2009, 64, S122-S138.	5.3	31
155	Do subjects with minimal motor features have prodromal Parkinson disease?. Annals of Neurology, 2018, 83, 562-574.	5.3	31
156	p75 Nerve growth factor receptor immunoreactivity in the human brainstem and spinal cord. Brain Research, 1992, 589, 115-123.	2.2	30
157	Age-related decreases in GTP-cyclohydrolase-I immunoreactive neurons in the monkey and human substantia nigra. Journal of Comparative Neurology, 2000, 426, 534-548.	1.6	30
158	Excitotoxic and metabolic damage to the rodent striatum: Role of the P75 neurotrophin receptor and glial progenitors. Journal of Comparative Neurology, 2002, 444, 291-305.	1.6	30
159	Injectable Hydrogels Providing Sustained Delivery of Vascular Endothelial Growth Factor are Neuroprotective in a Rat Model of Huntingtonâ€™s Disease. Neurotoxicity Research, 2010, 17, 66-74.	2.7	30
160	Issues regarding gene therapy products for Parkinson's disease: The development of CERE-120 (AAV-NTN) as one reference point. Parkinsonism and Related Disorders, 2007, 13, S469-S477.	2.2	29
161	Regulatable promoters and gene therapy for Parkinson's disease: Is the only thing to fear, fear itself?. Experimental Neurology, 2008, 209, 34-40.	4.1	29
162	Primate models of Parkinson's disease. Experimental Neurology, 2003, 183, 258-262.	4.1	28

#	Article	IF	Citations
163	Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinsonâ€™s disease. Npj Regenerative Medicine, 2022, 7, 24.	5.2	28
164	Response of the monkey cholinergic septohippocampal system to fornix transection: A histochemical and cytochemical analysis. Journal of Comparative Neurology, 1990, 298, 443-457.	1.6	27
165	Î±-Synuclein nonhuman primate models of Parkinsonâ€™s disease. Journal of Neural Transmission, 2018, 125, 385-400.	2.8	27
166	Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases. Drug Delivery and Translational Research, 2011, 1, 361-382.	5.8	26
167	Targeting Î±-Synuclein as a therapy for Parkinson's disease: The battle begins. Movement Disorders, 2017, 32, 203-207.	3.9	26
168	Neurogenesis of the magnocellular basal forebrain nuclei in the rhesus monkey. Journal of Comparative Neurology, 1990, 291, 637-653.	1.6	24
169	Neonatal immune-tolerance in mice does not prevent xenograft rejection. Experimental Neurology, 2014, 254, 90-98.	4.1	24
170	Disease Modification for Parkinson's Disease: Axonal Regeneration and Trophic Factors. Movement Disorders, 2018, 33, 678-683.	3.9	24
171	Inflammation in Experimental Models of Î±<scp>â€Synucleinopathies</scp>. Movement Disorders, 2021, 36, 37-49.	3.9	24
172	Analysis of age-related changes in psychosine metabolism in the human brain. PLoS ONE, 2018, 13, e0193438.	2.5	24
173	NGF receptor (p75)-immunoreactivity in the developing primate basal ganglia. Journal of Comparative Neurology, 1993, 327, 359-375.	1.6	22
174	Propagation of host disease to grafted neurons: Accumulating evidence. Experimental Neurology, 2009, 220, 224-225.	4.1	22
175	RET expression does not change with age in the substantia nigra pars compacta of rhesus monkeys. Neurobiology of Aging, 2006, 27, 857-861.	3.1	21
176	Can Intrabodies Serve as Neuroprotective Therapies for Parkinson's Disease? Beginning Thoughts. Journal of Parkinson's Disease, 2013, 3, 581-591.	2.8	18
177	Gene Therapy for Parkinsonâ€™s Disease: Still a Hot Topic?. Neuropsychopharmacology, 2015, 40, 255-256.	5.4	18
178	Low-Dose Maraviroc, an Antiretroviral Drug, Attenuates the Infiltration of T Cells into the Central Nervous System and Protects the Nigrostriatum in Hemiparkinsonian Monkeys. Journal of Immunology, 2019, 202, 3412-3422.	0.8	18
179	Does Developmental Variability in the Number of Midbrain Dopamine Neurons Affect Individual Risk for Sporadic Parkinsonâ€™s Disease?. Journal of Parkinson's Disease, 2020, 10, 405-411.	2.8	18
180	GDNF signaling in subjects with minimal motor deficits and Parkinson's disease. Neurobiology of Disease, 2021, 153, 105298.	4.4	18

#	Article	IF	Citations
181	Delivery of therapeutic molecules into the CNS. Progress in Brain Research, 2000, 128, 323-332.	1.4	17
182	Long-term gonadal hormone treatment and endogenous neurogenesis in the dentate gyrus of the adult female monkey. Experimental Neurology, 2010, 224, 252-257.	4.1	17
183	Enhanced CNS transduction from AAV.PHP.eB infusion into the cisterna magna of older adult rats compared to AAV9. Gene Therapy, 2022, 29, 390-397.	4.5	17
184	Tyrosine hydroxylase-immunoreactive somata within the primate subfornical organ: species specificity. Brain Research, 1988, 461, 221-229.	2.2	16
185	Chapter 15 Neuropathology of fetal nigra transplants for Parkinson's disease. Progress in Brain Research, 2000, 127, 333-344.	1.4	16
186	AAV2-Neurturin for Parkinsonâ€™s Disease: What Lessons Have We Learned?. Methods in Molecular Biology, 2016, 1382, 485-490.	0.9	16
187	In situ proximity labeling identifies Lewy pathology molecular interactions in the human brain. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	16
188	Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease. Journal of Neuroscience, 2020, 40, 3675-3691.	3.6	15
189	Parkinson's disease gene therapy: Will focused ultrasound and nanovectors be the next frontier?. Movement Disorders, 2019, 34, 1279-1282.	3.9	14
190	Stem Cells: Scientific and Ethical Quandaries of a Personalized Approach to Parkinson's Disease. Movement Disorders, 2020, 35, 1312-1314.	3.9	14
191	Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. Neurobiology of Disease, 2021, 148, 105184.	4.4	14
192	Neural Transplantation into the CNS: Selected Articles from the First Asnt Meeting. Cell Transplantation, 1995, 4, 1-1.	2.5	13
193	Widespread Striatal Delivery of GDNF from Encapsulated Cells Prevents the Anatomical and Functional Consequences of Excitotoxicity. Neural Plasticity, 2019, 2019, 1-9.	2.2	12
194	Loss of One Engrailed1 Allele Enhances Induced Î±-Synucleinopathy. Journal of Parkinson's Disease, 2019, 9, 315-326.	2.8	12
195	Mitomycin-C treatment during differentiation of induced pluripotent stem cell-derived dopamine neurons reduces proliferation without compromising survival or function inâ€‰vivo. Stem Cells Translational Medicine, 2021, 10, 278-290.	3.3	12
196	The first miracle in neurodegenerative disease: The discovery of oral levodopa. Brain Research Bulletin, 1999, 50, 377-378.	3.0	11
197	Making the counts count: the stereology revolution. Journal of Chemical Neuroanatomy, 2000, 20, 1-2.	2.1	10
198	Gene therapy approaches for the treatment of Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 84, 291-304.	1.8	9

#	Article	IF	Citations
199	Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2016, 6, 77-97.	2.8	9
200	A historical review of multiple system atrophy with a critical appraisal of cellular and animal models. Journal of Neural Transmission, 2021, 128, 1507-1527.	2.8	9
201	Viral vector-mediated gene therapy for Parkinson's disease. Clinical Neuroscience Research, 2001, 1, 496-506.	0.8	8
202	Fetal grafts for Parkinsonâ€™s disease: Decades in the making. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6332-6334.	7.1	8
203	Disease Modification Through Trophic Factor Delivery. Methods in Molecular Biology, 2018, 1780, 525-547.	0.9	7
204	SeqStain is an efficient method for multiplexed, spatialomic profiling of human and murine tissues. Cell Reports Methods, 2021, 1, 100006.	2.9	7
205	NGF receptor (p75)-immunoreactivity within hypoglossal motor neurons following axotomy in monkeys. Restorative Neurology and Neuroscience, 1992, 4, 411-417.	0.7	6
206	Parkinsonian monkeys with prior levodopaâ€induced dyskinesias followed by fetal dopamine precursor grafts do not display graftâ€induced dyskinesias. Journal of Comparative Neurology, 2017, 525, 498-512.	1.6	6
207	Long-term, stable, targeted biodelivery and efficacy of GDNF from encapsulated cells in the rat and Goettingen miniature pig brain. Current Research in Pharmacology and Drug Discovery, 2020, 1, 19-29.	3.6	6
208	Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Annals of Neurology, 2001, 49, 202-213.	5.3	6
209	The prion hypothesis of Parkinson's disease: This hot topic just got hotter. Movement Disorders, 2014, 29, 988-988.	3.9	5
210	The native form of Î±â€Synuclein: Monomer, tetramer, or a combination in equilibrium. Movement Disorders, 2015, 30, 1870-1870.	3.9	5
211	Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease. Movement Disorders, 2018, 33, 652-654.	3.9	5
212	Parkinson's disease and prion disease: Straining the comparison. Movement Disorders, 2015, 30, 1727-1727.	3.9	4
213	TDPâ€43 Proteinopathy: Aggregation and Propagation in the Pathogenesis of Amyotrophic Lateral Sclerosis. Movement Disorders, 2016, 31, 1139-1139.	3.9	4
214	A Failed Future. Movement Disorders, 2020, 35, 1299-1301.	3.9	4
215	Animal Rights Terrorists: What Every Neuroscientist Should Know. Journal of Neuroscience, 2009, 29, 11419-11420.	3.6	3
216	In Memorium: Roy A.E. Bakay, MD. Movement Disorders, 2013, 28, 1809-1810.	3.9	3

#	Article	IF	Citations
217	Knockout of p75^{NTR} Does Not Alter the Viability of Striatal Neurons Following a Metabolic or Excitotoxic Injury. Journal of Molecular Neuroscience, 2003, 20, 93-102.	2.3	2
218	RNA amplification of bromodeoxyuridine labeled newborn neurons in the monkey hippocampus. Journal of Neuroscience Methods, 2005, 144, 197-201.	2.5	2
219	Misfolded proteins in <scp>H</scp>untington disease fetal grafts: Further evidence of cellâ€toâ€cell transfer?. Annals of Neurology, 2014, 76, 20-21.	5.3	2
220	Mechanisms for cell-to-cell propagation no longer lag behind. Movement Disorders, 2016, 31, 1798-1799.	3.9	2
221	The use of aged monkeys to study pd: important roles in pathogenesis and experimental therapeutics. , 2008, , 77-85.		1
222	Celebrating neural repair. Journal of Comparative Neurology, 2009, 515, 1-3.	1.6	1
223	Reply to: â€œCell Therapy for Huntington's Disease: Learning from Failureâ€• Movement Disorders, 2021, 36, 788-789.	3.9	1
224	Connections of the hippocampal formation in humans: II. The endfolial fiber pathway. Journal of Comparative Neurology, 1997, 385, 352-371.	1.6	1
225	Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. , 0, .		1
226	B2 bradykinin receptor immunoreactivity in rat brain. Journal of Comparative Neurology, 2000, 427, 1-18.	1.6	1
227	Î²-secretase-1 (BACE1) expression in cerebral neocortex shows a modular distribution pattern: Inverse correlation with endogenous neuronal activity. Cell Biology International, 2008, 32, S10-S11.	3.0	0
228	Special issue on neural repair. Journal of Comparative Neurology, 2009, 515, spc1-spc1.	1.6	0
229	Special issue on neural repair. Journal of Comparative Neurology, 2009, 515, spc1-spc1.	1.6	0
230	Reply to: â€œBeing too inclusive about synuclein inclusionsâ€• Nature Medicine, 2010, 16, 961-961.	30.7	0
231	Preface. Movement Disorders, 2016, 31, 151-151.	3.9	0
232	What would Dr. James Parkinson think today? parcelling out the circuitry of levodopaâ€induced dyskinesias. Movement Disorders, 2017, 32, 483-484.	3.9	0
233	Cell Replacement Strategies for Parkinsonâ€™s Disease. Molecular and Translational Medicine, 2017, , 73-83.	0.4	0
234	Reply to: â€œToward a Personalized Approach to Parkinson's Cell Therapyâ€• Movement Disorders, 2020, 35, 2120-2121.	3.9	0

#	Article	IF	Citations
235	GENE AND CELLULAR TRANSPLANTATION THERAPIES FOR HUNTINGTON'S DISEASE. , 2008, , 267-294.		0
236	Introduction to the special ASNTR issue. Cell Transplantation, 2008, 17, 361-2.	2.5	0
237	The Unbearable Lightness of Brundin. Journal of Parkinson's Disease, 2022, 12, 1069-1072.	2.8	0